Abstract
Continuous intrathecal Baclofen application (ITB) through an intracorporeal pump system is widely used in adults and children with spasticity of spinal and supraspinal origin. Currently, about 1200 new ITB pump systems are implanted in Germany each year. ITB is based on an interdisciplinary approach with neurologists, rehabilitation specialists, paediatricians and neurosurgeons. We are presenting the proceedings of a consensus meeting organised by IAB—Interdisciplinary Working Group for Movement Disorders. The ITB pump system consists of the implantable pump with its drug reservoir, the refill port, an additional side port and a flexible catheter. Non-programmable pumps drive the Baclofen flow by the reservoir pressure. Programmable pumps additionally contain a radiofrequency control unit, an electrical pump and a battery. They have major advantages during the dose-finding phase. ITB doses vary widely between 10 and 2000 μg/day. For spinal spasticity, they are typically in the order of 100–300 μg/day. Hereditary spastic paraplegia seems to require particularly low doses, while dystonia and brain injury require particularly high ones. Best effects are documented for tonic paraspasticity of spinal origin and the least effects for phasic muscle hyperactivity disorders of supraspinal origin. Oral antispastics are mainly effective in mild spasticity. Botulinum toxin is most effective in focal spasticity. Myotomies and denervation operations are restricted to selected cases of focal spasticity. Due to its wide-spread distribution within the cerebrospinal fluid, ITB can tackle wide-spread and severe spasticity.
Similar content being viewed by others
References
Adib Saberi F, Dressler D (2013) Interdisziplinärer Arbeitskreis Bewegungsstörungen (IAB): an interdisciplinary working group for promoting multimodal therapy of movement disorders. J Neural Transm 120:705–710
Albright AL, Cervi A, Singletary J (1991) Intrathecal baclofen for spasticity in cerebral palsy. JAMA 265:1418–1422
Albright AL, Barry MJ, Shafton DH, Ferson SS (2001) Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 43:652–657
Allen NM, Lin JP, Lynch T, King MD (2014) Status dystonicus: a practice guide. Dev Med Child Neurol 56:105–112
Berger B, Vienenkoetter B, Korporal M, Rocco A, Meinck HM, Steiner T (2012) Accidental intoxication with 60 mg intrathecal baclofen: survived. Neurocrit Care 16:428–432
Bernards CM (2006) Cerebrospinal fluid and spinal cord distribution of baclofen and bupivacaine during slow intrathecal infusion in pigs. Anesthesiology 105:169–178
Bushman W, Steers WD, Meythaler JM (1993) Voiding dysfunction in patients with spastic paraplegia: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn 12:163–170
Curtis DR, Lodge D, Bornstein JC, Peet MJ (1981) Selective effects of (-)-baclofen on spinal synaptic transmission in the cat. Exp Brain Res 42:158–170
Dario A, Tomei G (2007) Management of spasticity in multiple sclerosis by intrathecal baclofen. Acta Neurochir Suppl 97:189–192
Dralle D, Müller H, Zierski J, Klug N (1985) Intrathecal baclofen for spasticity. Lancet 2:1003
Edsbagge M, Tisell M, Jacobsson L, Wikkelso C (2004) Spinal CSF absorption in healthy individuals. Am J Physiol Regul Integr Comp Physiol 287:R1450–R1455
Edsbagge M, Starck G, Zetterberg H, Ziegelitz D, Wikkelso C (2011) Spinal cerebrospinal fluid volume in healthy elderly individuals. Clin Anat 24:733–740
Flack SH, Bernards CM (2010) Cerebrospinal fluid and spinal cord distribution of hyperbaric bupivacaine and baclofen during slow intrathecal infusion in pigs. Anesthesiology 112:165–173
Francisco GE (2001) Intrathecal baclofen therapy for stroke-related spasticity. Top Stroke Rehabil 8:36–46
Green LB, Nelson VS (1999) Death after acute withdrawal of intrathecal baclofen: case report and literature review. Arch Phys Med Rehabil 80:1600–1604
Heetla HW, Staal MJ, Proost JH, van Laar T (2014) Clinical relevance of pharmacological and physiological data in intrathecal baclofen therapy. Arch Phys Med Rehabil (epub ahead)
Hoving MA, van Raak EP, Spincemaille GH, Palmans LJ, Sleypen FA, Vles JS, Dutch Study Group on Child Spasticity (2007) Intrathecal baclofen in children with spastic cerebral palsy: a double-blind, randomized, placebo-controlled, dose-finding study. Dev Med Child Neurol 49:654–659
Hugenholtz H, Nelson RF, Dehoux E (1993) Intrathecal baclofen - the importance of catheter position. Can J Neurol Sci 20:165–167
Kroin JS, Penn RD (1992) Cerebrospinal fluid pharmacokinetics of lumbar intrathecal baclofen. In: Lakke JPWF, Delhaas EM, Rutgers AWF (eds) Parenteral drug therapy in spasticity and Parkinson’s disease. The Parthenon Publishing Group Ltd., Casterton Hall, pp 67–78
Li Y, Li X, Harvey PJ (2004) Bennett DJ (2004) Effects of baclofen on spinal reflexes and persistent inward currents in motoneurons of chronic spinal rats with spasticity. J Neurophysiol 92:2694–2703
McCall TD, MacDonald JD (2006) Cervical catheter tip placement for intrathecal baclofen administration. Neurosurgery 59:634–640
Müller CA, Geisel O, Banas R, Heinz A (2014) Current pharmacological treatment approaches for alcohol dependence. Expert Opin Pharmacother 15:471–481
Newton JC, Harned ME, Sloan PA, Salles SS (2013) Trialing of intrathecal baclofen therapy for refractory stiff-person syndrome. Reg Anesth Pain Med 38:248–250
Ordia JI, Fischer E, Adamski E, Spatz EL (2002) Continuous intrathecal baclofen infusion delivered by a programmable pump for the treatment of severe spasticity following traumatic brain injury. Neuromodulation 5:103–107
Penn RD, Kroin JS (1984) Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1:1078
Pin TW, McCartney L, Lewis J, Waugh MC (2011) Use of intrathecal baclofen therapy in ambulant children and adolescents with spasticity and dystonia of cerebral origin: a systematic review. Dev Med Child Neurol 53:885–895
Santos ML, Mota-Miranda A, Alves-Pereira A, Gomes A, Correia J, Marçal N (2004) Intrathecal baclofen for the treatment of tetanus. Clin Infect Dis 38:321–328
Sato K, Morimoto K, Okamoto M, Nakamura Y, Otsuki S, Sato M (1990) An analysis of anticonvulsant actions of GABA agonists (progabide and baclofen) in the kindling model of epilepsy. Epilepsy Res 5:117–124
Shellock FG, Crivelli R, Venugopalan R (2008) Programmable infusion pump and catheter: evaluation using 3-tesla magnetic resonance imaging. Neuromodulation 11:163–170
Shirley KW, Kothare S, Piatt JH Jr, Adirim TA (2006) Intrathecal baclofen overdose and withdrawal. Pediatr Emerg Care 22:258–261
Tassëel Ponche S, Ferrapie AL, Chenet A, Menei P, Gambart G, Ménégalli Bogeli D, Perrouin Verbe B, Gay S, Richard I (2010) Intrathecal baclofen in cerebral palsy. A retrospective study of 25 wheelchair-assisted adults. Ann Phys Rehabil Med 53:483–498
Turner M, Nguyen HS, Cohen-Gadol AA (2012) Intraventricular baclofen as an alternative to intrathecal baclofen for intractable spasticity or dystonia: outcomes and technical considerations. J Neurosurg Pediatr 10:315–319
Voss W, Gad D, Mücke K-H, Christen H-J (2009) Intrathekale Baclofentherapie: palliativmaßnahme bei spastischen und dystonen Bewegungsstörungen. Monatsschr Kinderheilkd 2009:1–9
Watve SV, Sivan M, Raza WA, Jamil FF (2012) Management of acute overdose or withdrawal state in intrathecal baclofen therapy. Spinal Cord 50:107–111
Yang K, Wang D, Li YQ (2001) Distribution and depression of the GABA(B) receptor in the spinal dorsal horn of adult rat. Brain Res Bull 55:479–485
Acknowledgments
DD received honoraria for consultations from Allergan, Eisai/Solstice, Ipsen, Merz and Syntaxin. He is a shareholder in Allergan. He holds patents in botulinum toxin research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dressler, D., Berweck, S., Chatzikalfas, A. et al. Intrathecal Baclofen therapy in Germany: Proceedings of the IAB—Interdisciplinary Working Group for Movement Disorders Consensus Meeting. J Neural Transm 122, 1573–1579 (2015). https://doi.org/10.1007/s00702-015-1425-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-015-1425-1